48 assets in Esophageal Adenocarcinoma

Therapeutic assets addressing Esophageal Adenocarcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Capecitabine Esophageal Adenocarcinoma	I-Mab Biopharma US Limited	P3	B (63)
Cetuximab Esophageal Adenocarcinoma	BeOne Medicines	P2	B (63)
Oxaliplatin Esophageal Adenocarcinoma	I-Mab Biopharma US Limited	P3	B (62)
Tislelizumab Esophageal Adenocarcinoma	BeOne Medicines	P3	B (62)
Cis-Diamminedichloroplatinum Ii Esophageal Adenocarcinoma	Taiho Oncology, Inc.	P3	B (61)
Durvalumab Esophageal Adenocarcinoma	University of California, Irvine	P2	B (61)
Fluorouracilum Esophageal Adenocarcinoma	I-Mab Biopharma US Limited	P3	B (61)
Pembrolizumab Esophageal Adenocarcinoma	Diwakar Davar	P3	B (60)
Trastuzumab Esophageal Adenocarcinoma	Boehringer Ingelheim	P3	B (60)
Immunoglobulin G2, Anti-(Human Ctla-4 (Antigen)) (Human Monoclonal Cp-675206 Clone 11.2.1 Heavy Chain) Disulphide With Human Monoclonal Cp-675206 Clone 11.2.1 Light Chain, Dimer Esophageal Adenocarcinoma	University of California, Irvine	P2	B (59)
Levofolinic Acid Esophageal Adenocarcinoma	Taiho Oncology, Inc.	P3	B (59)
Zanidatamab Esophageal Adenocarcinoma	Boehringer Ingelheim	P3	B (59)
Givastomig Esophageal Adenocarcinoma	I-Mab Biopharma US Limited	P2	CCC (55)
Nivolumab Esophageal Adenocarcinoma	I-Mab Biopharma US Limited	P2	CCC (55)
Adenovirus 5/F35-Human Guanylyl Cyclase C-Padre Esophageal Adenocarcinoma	Thomas Jefferson University	P2	CCC (53)
Human Adenovirus C Serotype 5 Esophageal Adenocarcinoma	Thomas Jefferson University	P2	CCC (53)
Irinotecan Esophageal Adenocarcinoma	Taiho Oncology, Inc.	P2	CCC (51)
Metformin Esophageal Adenocarcinoma	Dan Zandberg	P2	CCC (51)
Rosiglitazone Esophageal Adenocarcinoma	Dan Zandberg	P2	CCC (51)
Tucatinib Esophageal Adenocarcinoma	Seagen, a wholly owned subsidiary of Pfizer	P2	CCC (51)
Futibatinib Esophageal Adenocarcinoma	Taiho Oncology, Inc.	P2	CCC (49)
Spartalizumab Esophageal Adenocarcinoma	SOLTI Breast Cancer Research Group	P2	CCC (48)
azd5863 Esophageal Adenocarcinoma	AstraZeneca	P1/2	CC (43)
Bgb-53038 Esophageal Adenocarcinoma	BeOne Medicines	P1	CC (43)
bnt141 Esophageal Adenocarcinoma	BioNTech SE	P1/2	CC (43)
Cabozantinib Esophageal Adenocarcinoma	Anwaar Saeed	P1/2	CC (43)
ide892 Esophageal Adenocarcinoma	IDEAYA Biosciences	P1	CC (43)
MAT2A-IN-9 Esophageal Adenocarcinoma	IDEAYA Biosciences	P1	CC (43)
Trastuzumab Deruxtecan Esophageal Adenocarcinoma	Boehringer Ingelheim	P1/2	CC (43)
Trastuzumab Emtansine Esophageal Adenocarcinoma	Boehringer Ingelheim	P1/2	CC (43)
Zongertinib Esophageal Adenocarcinoma	Boehringer Ingelheim	P1/2	CC (43)
Cabotamig Esophageal Adenocarcinoma	Arbele Pty Ltd	P1	CC (42)
Sigvotatug Vedotin Esophageal Adenocarcinoma	Seagen, a wholly owned subsidiary of Pfizer	P1	CC (42)
Bl-M05D1 Esophageal Adenocarcinoma	SystImmune Inc.	P1	C (39)
Carboplatin Esophageal Adenocarcinoma	Blueprint Medicines Corporation	P1	C (39)
Cirtociclib Esophageal Adenocarcinoma	Blueprint Medicines Corporation	P1	C (39)
Disp-10 Esophageal Adenocarcinoma	Dispatch Biotherapeutics	P1	C (39)
Docetaxel Esophageal Adenocarcinoma	Kyowa Kirin Co., Ltd.	P1	C (39)
Fulvestrant Esophageal Adenocarcinoma	Blueprint Medicines Corporation	P1	C (39)
kk2269 Esophageal Adenocarcinoma	Kyowa Kirin Co., Ltd.	P1	C (39)
m28z1xxpd1dnr car Esophageal Adenocarcinoma	Memorial Sloan Kettering Cancer Center	P1	C (39)
Nrm-823 Esophageal Adenocarcinoma	Normunity AccelCo, Inc.	P1	C (39)
pf-08046876 Esophageal Adenocarcinoma	Pfizer	P1	C (39)
Plx-61639 Esophageal Adenocarcinoma	Plexium, Inc.	P1	C (39)
prt7732 Esophageal Adenocarcinoma	Prelude Therapeutics	P1	C (39)
Ribociclib Esophageal Adenocarcinoma	Blueprint Medicines Corporation	P1	C (39)
tj033721 Esophageal Adenocarcinoma	I-Mab Biopharma US Limited	P1	C (39)
Human Interleukin 2 (Il2, T-Cell Growth Factor, Tcgf) (2-133) Variant (A1 Deleted, Pro65>Lys, Cys125>Ser), Non-Glycosylated, Produced In Escherichia Coli, Conjugated At N6 Of K65 With A Peg Derivative (30Kda) Esophageal Adenocarcinoma	Sanofi	P2	C (33)